Abstract:Drug-induced blockade of the human ether-à-go-go-related gene (hERG) channel is today considered the main cause of cardiotoxicity in postmarketing surveillance. Hence, several ligand-based approaches were developed in the last years and are currently employed in the early stages of a drug discovery process for in silico cardiac safety assessment of drug candidates. Herein, we present the first structure-based classifiers able to discern hERG binders from nonbinders. LASSO regularized support vector machines were applied to integrate docking scores and protein–ligand interaction fingerprints. A total of 396 models were trained and validated based on: (i) high-quality experimental bioactivity information returned by 8337 curated compounds extracted from ChEMBL (version 25) and (ii) structural predictor data. Molecular docking simulations were performed using GLIDE and GOLD software programs and four different hERG structural models, namely, the recently published structures obtained by cryoelectron microscopy (PDB codes: 5VA1 and 7CN1) and two published homology models selected for comparison. Interestingly, some classifiers return performances comparable to ligand-based models in terms of area under the ROC curve (AUCMAX = 0.86 ± 0.01) and negative predictive values (NPVMAX = 0.81 ± 0.01), thus putting forward the herein proposed computational workflow as a valuable tool for predicting hERG-related cardiotoxicity without the limitations of ligand-based models, typically affected by low interpretability and a limited applicability domain. From a methodological point of view, our study represents the first example of a successful integration of docking scores and protein–ligand interaction fingerprints (IFs) through a support vector machine (SVM) LASSO regularized strategy. Finally, the study highlights the importance of using hERG structural models accounting for ligand-induced fit effects and allowed us to select the best-performing protein conformation (made available in the Supporting Information, SI) to be employed for a reliable structure-based prediction of hERG-related cardiotoxicity.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jcim.1c00744.Top views of the BS of all of the employed protein models and the number of active and inactive compounds as a consequence of the selected activity and inactivity thresholds (Figures S1 and S2 and Tables S1) (PDF)Kolmogorov–Smirnov test p-values summarizing the difference in docking score distributions between hERG binders and nonbinders, the SE and SP of all of the developed models, the BS volumes (Å3) of all of the used hERG models, and the interactions responsible for a lower IC50 based on the KS test performed on the IFs returned by all of the considered protein models (Tables S2–S6) (PDF)List of the compounds belonging to the hERG-DB, including SMILES strings and corresponding IC50 values (XLSX)Results of the performed docking simulations including docking scores and molecular interaction fingerprints (ZIP)Results of the performed docking simulations including molecular interaction fingerprints (ZIP)5VA1-IFD-1, 5VA1-IFD-2, 5VA1-IFD-3, 5VA1-IFD-4, and 5VA1-IFD-5 conformations as. pdb files (ZIP)This article has not yet been cited by other publications.

Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

The interactions between hERG potassium channel and blockers.

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Physicochemical Basis for Binding and Voltage‐Dependent Block of Herg Channels by Structurally Diverse Drugs

Recent Developments in Computational Prediction of Herg Blockage

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models

A novel structure-based virtual screening model for the hERG channel blockers.

Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects

Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors

Structural modeling of hERG channel-drug interactions using Rosetta

Optimising experimental designs for model selection of ion channel drug binding mechanisms

Experimentally Validated Modeling of Dynamic Drug-HERG Channel Interactions Reproducing the Binding Mechanisms and its Importance in Action Potential Duration.

Physicochemical features of the HERG channel drug binding site

In Silico Prediction Of Herg Potassium Channel Blockage By Chemical Category Approaches

Novel Intramolecular Photoinduced Electron Transfer-Based Probe for the Human Ether-a-go-go-Related Gene (herg) Potassium Channel

Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study

Admet Evaluation In Drug Discovery. 12. Development Of Binary Classification Models For Prediction Of Herg Potassium Channel Blockage

Process in the Research on Chemical Modification of Drugs with Low Herg Cardiac Toxicity